Drugs in MeSH Category Protective Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sagent Pharms Inc	MESNA	mesna	INJECTABLE;INTRAVENOUS	090913-001	Apr 13, 2010	AP	RX	No	No
Baxter Hlthcare	MESNEX	mesna	TABLET;ORAL	020855-001	Mar 21, 2002	AB	RX	Yes	Yes
Ingenus Pharms Llc	MESNA	mesna	TABLET;ORAL	218871-001	Jan 13, 2025	AB	RX	No	No
Hikma	MESNA	mesna	INJECTABLE;INTRAVENOUS	075739-001	Jan 9, 2004	AP	RX	No	No
Gland	MESNA	mesna	INJECTABLE;INTRAVENOUS	206992-001	Dec 18, 2017	AP	RX	No	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Protective Agents

Last updated: April 24, 2026

What counts as “Protective Agents” in MeSH and why it matters for market sizing?

“NLM MeSH Class: Protective Agents” is a functional drug category used in MeSH indexing and signal mining. It does not map 1:1 to a single commercial therapeutic class. It is a mixed basket of agents that protect tissue surfaces, stabilize barrier function, reduce chemical injury, or form protective coatings, alongside drugs used to prevent or mitigate damage from inflammation, toxins, or gastric/ulcerogenic processes.

For market and patent analysis, this category is best treated as a cross-therapeutic set that includes (typical examples) gastric/upper GI mucosal protectants and barrier agents, plus selected agents used for tissue protection in other organ systems where MeSH indexing places them under protective activity. The category structure means:

• Commercial competitors can sit in adjacent therapeutic areas (gastroenterology, hepatology, dermatology, ophthalmology, and wound care).
• Patent estates often come from platform formulations, new salts/complexes, or new delivery systems rather than new “molecule first” innovation.

Which products dominate “Protective Agents” revenue pools?

Within MeSH “protective” signals, the revenue gravity typically concentrates in widely used GI and mucosal-protection products, and in a smaller set of specialty protectants where the indication is tightly defined (for example, mucositis prevention or local barrier protection). The highest-volume commercial anchor products generally share one trait: clinicians use them broadly and repeatedly, which supports persistent demand even as individual formulations face patent expiry.

Typical high-impact market clusters:

• Upper GI mucosal protectants and ulcer-prevention therapies (pharmacologic agents that protect the gastric lining or prevent injury).
• Barrier-forming local therapies (coatings, film-formers, and local protectants in wound/ulcer settings).
• Protection adjuncts in inflammatory or injury pathways (agents used to prevent tissue damage in defined clinical contexts).

Because MeSH “Protective Agents” is not a single ATC code, the patent landscape analysis below is structured to reflect what drives enforceable exclusivity in these clusters: composition of matter, method-of-use, and formulation/medical device-adjacent protection.

---

How does the patent landscape usually look for Protective Agents?

The protective-agent basket shows a common patent architecture across geographies:

1) Composition-of-matter patents (MoA-level, then reformulation)

Many earliest protected molecules enter markets with MoC patents followed by long tail exclusivity from:

• polymorphs and crystalline forms
• salts/solvates
• prodrugs
• stereoisomers
• fixed-dose combinations with acid suppression or anti-inflammatories

In “protective” categories, reformulation is common because clinical benefit often depends on local exposure and pharmacokinetics at the mucosal surface, which creates a path for follow-on patents.

2) Method-of-use patents tied to narrower clinical positioning

Protective agents frequently receive additional exclusivity for:

• specific patient subgroups (for example, high-risk ulcer patients)
• specific durations or prevention vs treatment claims
• endpoints (healing rates, recurrence prevention, and symptom indices)

3) Formulation patents and delivery patents

Protective effects are strongly formulation-dependent. Patents commonly cover:

• controlled release matrices
• mucoadhesive or barrier-forming drug release profiles
• protective coating compositions
• device-assisted delivery systems

4) Regulatory exclusivity as a parallel driver

Even when patent claims narrow, regulatory data exclusivity and market exclusivity in key markets can maintain sales during generic entry windows. This matters for protective agents because many incremental innovations are filed as line extensions.

---

Where are patent “cliffs” most likely in Protective Agents?

Patent cliffs in this segment usually occur in three scenarios:

1. Loss of primary MoC protection for anchor molecules
   After 10 to 20 years from filing, follow-on estates are tested against generic manufacturing and label carve-outs.

2. Follow-on patents fail to sustain broad claims
   Protective agents often have tight claim language tied to specific formulation characteristics. Generic substitutes can avoid infringement by adjusting excipients, release profile, or manufacturing steps.

3. Claims are weakened by prosecution history and claim narrowing
   Protective formulations can face active amendments during prosecution, limiting scope and making design-around easier.

Business implication: the market dynamics for “Protective Agents” often shift from brand-led dominance to multiple generic entrants with label and formulation differentiation, then back to brand advantage only where the company controls a higher-value niche endpoint or delivery system.

---

What patent timelines typically govern competitive entry?

Even without mapping a single product definition to the entire MeSH class, Protective Agents are usually structured around standard lifecycle timing:

• Early stage (0-5 years from launch): active primary claims dominate; follow-on filings begin.
• Mid stage (5-12 years): second-wave reformulation and indication-specific patents extend runway.
• Late stage (12+ years): challenges and generic launch planning accelerate around expiration and final regulatory status.

In protective agents, launch strategy often hinges on whether the competitor can launch with:

• a label that avoids method-of-use infringement
• a formulation that avoids infringement of release or coating claims
• a manufacturing process that avoids literal claim coverage

---

How do market dynamics respond after exclusivity loss?

Loss of exclusivity in protective agents typically drives:

• price compression for the protected indication and form
• rapid substitution when clinical differentiation is not strongly evidenced
• fragmentation into multiple generic SKUs and pack sizes
• continued brand sales where formulation-specific evidence supports a remaining premium position

Clinical practice tends to be pragmatic: if the protective endpoint is not uniquely tied to the branded formulation, switching is fast. If the branded product demonstrates superior mucosal coverage, healing endpoints, or reduced adverse event profiles, payers and clinicians may keep a premium product longer.

---

What does a “defensibility map” look like for brands in this category?

The patent defensibility of protective-agent portfolios is usually built around three pillars:

A) Breadth of formulation claims

Stronger portfolios cover release kinetics and coating behavior with measurable parameters and manufacturing controls that are hard to replicate exactly.

B) Evidence-to-claim alignment

Where clinical trials support the specific protective mechanism and endpoint, method-of-use claims have better survival odds under enforcement.

C) Label strategy

If the brand’s remaining patents protect narrowly defined populations or protocols, the brand must also protect those labels in regulatory updates. Otherwise, the commercial advantage is lost even if patents survive.

---

Which patent strategies are most effective for companies in Protective Agents?

Commonly effective strategies:

• Layering: filing follow-on patents before primary expiry, especially on formulation and delivery parameters.
• Claim diversification: combining MoC, formulation, and method-of-use claims so one axis is not the single point of failure.
• Design-around resistance: drafting claims so that alternative excipient choices do not break infringement (or using dependent claims that remain enforceable).
• Global prosecution discipline: minimizing claim narrowing that reduces enforceability in key markets.

Common weak points:

• overly narrow formulation definitions that are easy to design around with excipient substitutions
• method-of-use claims that depend on trial endpoints that do not consistently appear in real-world outcomes
• indication switching where post-launch evidence leads to label changes that undermine earlier claim narratives

---

What are the investor and R&D implications for entry and partnering?

Investors and acquirers typically underwrite protective-agent deals based on:

• the location of the next major exclusivity expiration in the core revenue product
• whether the portfolio includes “secondary” patents that survive design-around
• the degree of brand premium supported by measurable protective endpoints

R&D teams screen internal programs for:

• “must be protected” drug-device or formulation innovations
• clear endpoints that connect to method-of-use claims
• differentiation that is not only biological but also formulation mechanics (release time, mucosal residence, coating durability)

---

Key Takeaways

• “Protective Agents” in MeSH is a functional basket, not a single therapeutic class, so market dynamics depend on GI mucosal protectants and formulation-driven protectants with cross-indication competition.
• The patent landscape is typically driven by follow-on protection: formulation/delivery and method-of-use claims often matter as much as primary MoC.
• Post-expiry competition usually triggers rapid price compression and generic substitution, unless the brand’s protective effect is tightly tied to a formulation mechanism with defensible claims.
• The most durable portfolios in this area combine broad defensibility in formulation and aligned clinical evidence for method-of-use.

FAQs

1. Is MeSH “Protective Agents” the same as an ATC therapeutic class?
   No. It is an MeSH indexing category that cuts across multiple therapeutic domains and includes diverse protective mechanisms.

2. What patent types most often extend exclusivity in this segment?
   Formulation and delivery patents, plus method-of-use and indication-specific follow-on patents.

3. Do generic entrants usually match branded protective claims?
   They can often design around formulation-specific claims or avoid narrow method-of-use label positioning, leading to fast substitution.

4. What determines whether a brand keeps pricing power after expiry?
   Whether the protective effect is measurably tied to branded formulation mechanics and supported by evidence that persuades clinicians and payers.

5. Where should R&D focus to create enforceable protection?
   On protect-by-design formulation parameters and claim sets that remain valid under manufacturing and label design-around.

---

References

1. National Library of Medicine. MeSH (Medical Subject Headings). MeSH Browser. https://meshb.nlm.nih.gov/
2. European Patent Office (EPO). Patent law and patentability resources (general framework). https://www.epo.org/